Stockscreener 앱 받기
17.28
5.05%
0.83
시간 외 거래:
17.28
전일 마감가:
$16.45
열려 있는:
$16.31
하루 거래량:
538.48K
Relative Volume:
0.51
시가총액:
$797.07M
수익:
$681.75M
순이익/손실:
$70.47M
주가수익비율:
192.00
EPS:
0.09
순현금흐름:
$173.19M
1주 성능:
+0.58%
1개월 성능:
+4.63%
6개월 성능:
-36.49%
1년 성능:
-44.33%
1일 변동 폭
$16.24
$17.53
1주일 범위
$16.09
$17.53
52주 변동 폭
$11.16
$35.95
Pacira Biosciences Inc Stock (PCRX) Company Profile
명칭
Pacira Biosciences Inc
전화
813-553-6680
주소
5401 WEST KENNEDY BOULEVARD, TAMPA, NJ
Pacira Biosciences Inc Stock (PCRX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2023-12-20 | 개시 | Raymond James | Outperform |
| 2023-08-03 | 업그레이드 | TD Cowen | Market Perform → Outperform |
| 2023-01-31 | 재개 | Wedbush | Outperform |
| 2022-10-21 | 재개 | Jefferies | Buy |
| 2022-01-03 | 재개 | JP Morgan | Overweight |
| 2021-07-26 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2021-04-21 | 재개 | JP Morgan | Neutral |
| 2021-04-09 | 개시 | Berenberg | Buy |
| 2021-04-07 | 재개 | RBC Capital Mkts | Outperform |
| 2021-02-11 | 다운그레이드 | Northland Capital | Outperform → Market Perform |
| 2021-01-21 | 다운그레이드 | SVB Leerink | Outperform → Mkt Perform |
| 2020-09-21 | 업그레이드 | Northland Capital | Market Perform → Outperform |
| 2020-07-06 | 재확인 | Needham | Buy |
| 2020-05-27 | 개시 | Guggenheim | Neutral |
| 2020-04-07 | 개시 | Northland Capital | Outperform |
| 2020-03-20 | 업그레이드 | SVB Leerink | Mkt Perform → Outperform |
| 2020-02-24 | 재확인 | H.C. Wainwright | Buy |
| 2020-01-24 | 개시 | SunTrust | Buy |
| 2020-01-23 | 개시 | SunTrust | Buy |
| 2019-11-06 | 개시 | BTIG Research | Buy |
| 2019-06-11 | 개시 | Barclays | Overweight |
| 2019-05-06 | 업그레이드 | Mizuho | Underperform → Neutral |
| 2019-05-02 | 업그레이드 | Stifel | Sell → Hold |
| 2019-02-01 | 다운그레이드 | Mizuho | Neutral → Underperform |
| 2018-08-06 | 다운그레이드 | BofA/Merrill | Buy → Neutral |
| 2018-04-09 | 재확인 | H.C. Wainwright | Buy |
| 2018-03-21 | 재확인 | Mizuho | Neutral |
| 2018-02-16 | 다운그레이드 | Needham | Buy → Hold |
| 2018-01-19 | 개시 | Seaport Global Securities | Buy |
| 2018-01-04 | 재확인 | Canaccord Genuity | Buy |
| 2018-01-03 | 개시 | Leerink Partners | Mkt Perform |
모두보기
Pacira Biosciences Inc 주식(PCRX)의 최신 뉴스
Insights into Pacira BioSciences's Upcoming Earnings - Benzinga
Pacira BioSciences Inc (PCRX) Q3 2024: Everything You Need To Kn - GuruFocus.com
Pacira BioSciences, Inc. (NASDAQ:PCRX) Receives Consensus Recommendation of "Hold" from Analysts - MarketBeat
Trading (PCRX) With Integrated Risk Controls - Stock Traders Daily
Rice Hall James & Associates LLC Sells 730,288 Shares of Pacira BioSciences, Inc. (NASDAQ:PCRX) - MarketBeat
Pacira BioSciences (PCRX) Set to Announce Quarterly Earnings on Wednesday - MarketBeat
Allspring Global Investments Holdings LLC Buys 93,497 Shares of Pacira BioSciences, Inc. (NASDAQ:PCRX) - MarketBeat
Pacira to Report Third Quarter 2024 Financial Results on Wednesday November 6, 2024 - GlobeNewswire
Assenagon Asset Management S.A. Buys 419,656 Shares of Pacira BioSciences, Inc. (NASDAQ:PCRX) - MarketBeat
Shawn Cross appointed as chief financial officer for Pacira Biosciences - Pharmafile
When the Price of (PCRX) Talks, People Listen - Stock Traders Daily
Pacira BioSciences appoints Shawn Cross as CFO By Investing.com - Investing.com Australia
Pacira BioSciences appoints Shawn Cross as CFO - Investing.com
Are Options Traders Betting on a Big Move in Pacira BioSciences (PCRX) Stock? - MSN
Pacira BioSciences Appoints Shawn Cross As Chief Financial Officer - citybiz
Pacira BioSciences Names Shawn Cross Chief Financial Officer - MarketWatch
Pacira BioSciences Appoints Shawn Cross as Chief Financial Officer - GlobeNewswire
Q1 EPS Estimate for Pacira BioSciences Reduced by Analyst - MarketBeat
Pacira BioSciences, Inc. (NASDAQ:PCRX) Shares Purchased by Wedge Capital Management L L P NC - MarketBeat
Pacira BioSciences Inc (PCRX) may enjoy gains as insiders got busy in the recent days - Knox Daily
Was Pacira BioSciences Inc (PCRX)’s session last reading good? - US Post News
(PCRX) Trading Advice - Stock Traders Daily
A company insider recently sold 500 shares of Pacira BioSciences Inc [PCRX]. Should You Sale? - Knox Daily
What is the investor’s view on Pacira BioSciences Inc (PCRX)? - US Post News
Analysts Set Pacira BioSciences, Inc. (NASDAQ:PCRX) PT at $24.20 - MarketBeat
Analytical Overview: Pacira BioSciences Inc (PCRX)’s Ratios Tell a Financial Story - The Dwinnex
Pacira BioSciences, Inc. (NASDAQ:PCRX) Shares Sold by Bank of Montreal Can - MarketBeat
PCRX stock rated a Sell by Truist - Knox Daily
A Look at Pacira BioSciences Inc (PCRX) Shares in the Recent Past Indicates Growth - SETE News
Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - The Manila Times
Sei Investments Co. Sells 279,140 Shares of Pacira BioSciences, Inc. (NASDAQ:PCRX) - MarketBeat
Are Pacira BioSciences, Inc.'s (NASDAQ:PCRX) Mixed Financials Driving The Negative Sentiment? - Simply Wall St
The three-year loss for Pacira BioSciences (NASDAQ:PCRX) shareholders likely driven by its shrinking earnings - Yahoo Finance
Pacira BioSciences (NASDAQ:PCRX) Price Target Raised to $15.00 at Royal Bank of Canada - MarketBeat
Pacira's Exparel Receives Permanent New Product-Specific J-Code - Zacks Investment Research
Pacira wins Exparel Medicare J-code (NASDAQ:PCRX) - Seeking Alpha
Pacira BioSciences Announces New Product-Specific J-Code for EXPAREL Effective January 1, 2025 - GlobeNewswire
CMS grants new J-code for Pacira's non-opioid pain therapy - Investing.com
Pacira BioSciences Inc (PCRX)’s stock rises to 15.30 per share - US Post News
Pacira BioSciences' SWOT analysis: stock faces patent challenges amid growth initiatives - Investing.com India
Pacira BioSciences, Inc. (NASDAQ:PCRX) Shares Acquired by Dimensional Fund Advisors LP - MarketBeat
Pacira Pharmaceuticals Announces CFO Transition and Interim Replacement - TipRanks
Marshall Wace LLP Acquires 159,791 Shares of Pacira BioSciences, Inc. (NASDAQ:PCRX) - MarketBeat
Pacira to present new gene therapy data for knee osteoarthritis By Investing.com - Investing.com Australia
Doma Perpetual Capital Management LLC Has $28.63 Million Stock Position in Pacira BioSciences, Inc. (NASDAQ:PCRX) - MarketBeat
Pacira Announces the Presentation of 104-Week Safety and - GlobeNewswire
Pacira to present new gene therapy data for knee osteoarthritis - Investing.com
Pacira BioSciences (NASDAQ:PCRX) Shares Gap Up After Analyst Upgrade - MarketBeat
DOMA Perpetual Sends Letter to Board of Directors of Pacira Biosciences to Immediately Accelerate and Increase its Share Buyback Program to Enhance Return to Shareholders - PR Newswire
Pacira BioSciences (NASDAQ:PCRX) Price Target Increased to $18.00 by Analysts at Jefferies Financial Group - MarketBeat
Expert Ratings For Pacira BioSciences - Benzinga
Pacira Biosciences Inc (PCRX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.88%
0.42%
자본화:
|
볼륨(24시간):